Drug Information

Drug General Information
Drug ID
D0A1ZQ
Former ID
DCL000342
Drug Name
SU-6668
Drug Type
Small molecular drug
Indication Advanced solid tumor [ICD9: 140-199; ICD10:C00-C75, C7A, C7B] Phase 1 [527156], [542760]
Therapeutic Class
Anticancer Agents
Company
Pfizer; Sugen
Structure
Download
2D MOL

3D MOL
Formula
C18H18N2O3
InChI
InChI=1S/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19H,7-8H2,1-2H3,(H,20,23)(H,21,22)/b14-9-
InChIKey
NHFDRBXTEDBWCZ-ZROIWOOFSA-N
PubChem Compound ID
5329099
PubChem Substance ID
527809, 8034459, 11061326, 12015385, 14874233, 39301724, 53787898, 57287542, 57361293, 75555598, 81049299, 89388569, 99437172, 103175695, 113911629, 124757275, 125164079, 134338996, 134339167, 134964221, 135134779, 135182126, 135698723, 136340186, 136348238, 136367533, 136367774, 142063014, 143497361, 152234911, 152258241, 152344216, 160647077, 162011789, 162037617, 162202670, 163685934, 174561004, 177748855, 180386845, 185964372, 198939270, 204362248, 223366147, 223379505, 223705143, 226502638, 241376394, 242060022, 243278051
Target and Pathway
Target(s) Platelet-derived growth factor receptor Target Info Inhibitor [536137], [536474]
Vascular endothelial growth factor receptor 2 Target Info Inhibitor [536137], [536474]
Aurora kinase A Target Info Inhibitor [536137], [536474]
Basic fibroblast growth factor receptor 1 Target Info Inhibitor [536137], [536474]
Aurora kinase B Target Info Inhibitor [536137], [536474]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Cytokine-cytokine receptor interaction
Endocytosis
PI3K-Akt signaling pathway
VEGF signaling pathway
Focal adhesion
Proteoglycans in cancerhsa04114:Oocyte meiosishsa04010:MAPK signaling pathway
Adherens junction
Signaling pathways regulating pluripotency of stem cells
Regulation of actin cytoskeleton
Pathways in cancer
Proteoglycans in cancer
Prostate cancer
Melanoma
Central carbon metabolism in cancer
NetPath Pathway IL2 Signaling PathwayNetPath_11:TCR Signaling Pathway
PANTHER Pathway Angiogenesis
VEGF signaling pathwayP00005:Angiogenesis
FGF signaling pathway
Pathway Interaction Database HIF-2-alpha transcription factor network
Beta3 integrin cell surface interactions
Signaling events mediated by TCPTP
SHP2 signaling
S1P1 pathway
VEGF and VEGFR signaling network
Integrins in angiogenesis
Signaling events mediated by VEGFR1 and VEGFR2
Notch-mediated HES/HEY networkaurora_b_pathway:Aurora B signaling
Signaling by Aurora kinases
Integrin-linked kinase signaling
PLK1 signaling events
Aurora A signalingglypican_1pathway:Glypican 1 network
Syndecan-4-mediated signaling events
N-cadherin signaling events
FGF signaling pathwayaurora_b_pathway:Aurora B signaling
Aurora C signaling
FOXM1 transcription factor network
Aurora A signaling
Reactome Neurophilin interactions with VEGF and VEGFR
VEGF binds to VEGFR leading to receptor dimerization
Integrin cell surface interactions
EPHA-mediated growth cone collapse
VEGFA-VEGFR2 Pathway
VEGFR2 mediated cell proliferationR-HSA-174178:APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
Regulation of PLK1 Activity at G2/M TransitionR-HSA-174178:APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
Separation of Sister Chromatids
Resolution of Sister Chromatid Cohesion
RHO GTPases Activate Formins
Mitotic Prometaphase
WikiPathways Focal Adhesion
Nifedipine Activity
Cardiac Progenitor Differentiation
Signaling by VEGF
AngiogenesisWP437:EGF/EGFR Signaling Pathway
JAK/STAT
Gastric Cancer Network 1
Integrated Breast Cancer Pathway
APC/C-mediated degradation of cell cycle proteinsWP51:Regulation of Actin Cytoskeleton
Endochondral Ossification
MAPK Signaling Pathway
Mesodermal Commitment Pathway
Hair Follicle Development: Induction (Part 1 of 3)
Integrated Pancreatic Cancer Pathway
Signaling Pathways in Glioblastoma
Neural Crest Differentiation
Signaling by FGFRWP2757:Mitotic Metaphase and Anaphase
Mitotic Prometaphase
Regulation of Microtubule Cytoskeleton
miR-targeted genes in lymphocytes - TarBase
miR-targeted genes in epithelium - TarBase
APC/C-mediated degradation of cell cycle proteins
References
Ref 527156A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs. 2004 Nov;22(4):459-66.
Ref 542760(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7816).
Ref 536137Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. Clin Cancer Res. 2005 Sep 1;11(17):6240-6.
Ref 536474A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.